Caribou Biosciences (CRBU) Stock Forecast & Price Target

Caribou Biosciences is attractive because its chRDNA CRISPR platform offers improved specificity, fewer IP complexities, and pharma validation from Pfizer, while its focus on validated targets such as CD19 and BCMA supports a relatively higher probability of success than many early gene-editing peers. The company’s allogeneic CAR-T programs also include design features aimed at better durability, including PD1 knockout, HLA-E knock-in, and HLA partial matching, which could address a key weakness in the crowded cell-therapy landscape. Financially, 1Q26 net loss narrowed to $0.26 per share, cash and marketable securities were $118.6M, and that runway into 2H27 helps support the view that upcoming 2H25 clinical data could be a meaningful value catalyst.

Caribou Biosciences is facing a fundamentally weakened outlook because it has announced plans to discontinue further development of both clinical allogeneic CAR-T programs, vispa-cel and CB-011, while also exploring strategic alternatives after citing a challenging financing environment and lack of capital availability. The company’s decision to complete most of the clinical discontinuation and workforce reduction in 4Q26 underscores how limited its near-term operating flexibility has become, and it signals elevated execution, regulatory, and clinical risk across the remaining pipeline. With a discounted cash flow framework still assigning only 60% and 35% approval probabilities to vispa-cel and CB-011 respectively, the profile remains burdened by weak commercialization visibility, competition, and long-term dilution risk.